Nephrology Doctors in Port Washington, NY Accepting Medicare

6 Nephrology doctors found. Showing 1 - 6

Joel Blush, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 50 Seaview Blvd, Port Washington, NY 11050 Phone: 516-484-6093    Fax: 516-484-6180

Helen Jin, M.D. Internal Medicine - Nephrology Medicare: Medicare Enrolled Practice Location: 50 Seaview Blvd, Port Washington, NY 11050 Phone: 516-484-6093    Fax: 516-484-6180

Lionel U Mailloux, MD Internal Medicine - Nephrology Medicare: Not Enrolled in Medicare Practice Location: 50 Seaview Blvd, Port Washington, NY 11050 Phone: 516-484-6093    Fax: 516-484-6180

Mary C Mallappallil, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 50 Seaview Blvd, Port Washington, NY 11050 Phone: 516-484-6093    Fax: 516-484-6180

Dr. Howard Paul Furst, MD Internal Medicine - Nephrology Medicare: Not Enrolled in Medicare Practice Location: 7 Luckenbach Ln, Port Washington, NY 11050 Phone: 516-944-0217

Jasmeet Kaur, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 50 Seaview Blvd, Port Washington, NY 11050 Phone: 516-484-6093

News Archive

Uroglide technology could improve comfort for catheter users

A new pharmaceutical product that could significantly improve quality of life for catheter users all over the world is to be developed by Queen's University Belfast after it won a national award.

Significant progress in the enrollment of beneficiaries in the Medicare drug discount card program

America's health insurance plans today reported significant progress in the enrollment of beneficiaries in the Medicare-endorsed prescription drug discount card program.

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

Intarcia Therapeutics has announced final results from a Phase 2 study of omega interferon with or without ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

DARA BioSciences, Inc. announced today that on April 26, 2010, DARA Therapeutics, a subsidiary of DARA BioSciences, and the Division of Cancer Prevention, National Cancer Institute (NCI), National Institutes of Health (NIH), entered into a Clinical Trials Agreement to advance the clinical study of KRN5500 for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) in patients with cancer. Under the terms of the collaboration, NCI will fund the studies and DARA will supply KRN5500 and placebo.

Research shows how mutation linked with CLN3-Batten disease could lead to vision loss

Progressive vision loss, and eventually blindness, are the hallmarks of juvenile neuronal ceroid lipofuscinosis (JNCL) or CLN3-Batten disease.

Read more Medical News

› Verified 7 days ago